Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Amgen Inc.
IndexS&P 500 P/E22.55 EPS (ttm)6.53 Insider Own0.10% Shs Outstand759.61M Perf Week10.15%
Market Cap111.86B Forward P/E16.38 EPS next Y8.99 Insider Trans4.98% Shs Float758.78M Perf Month5.30%
Income5.01B PEG2.43 EPS next Q2.11 Inst Own81.70% Short Float1.45% Perf Quarter20.65%
Sales19.46B P/S5.75 EPS this Y20.30% Inst Trans-0.07% Short Ratio2.98 Perf Half Y33.46%
Book/sh32.12 P/B4.58 EPS next Y6.71% ROA7.70% Target Price144.90 Perf Year29.23%
Cash/sh34.48 P/C4.27 EPS next 5Y9.27% ROE22.00% 52W Range107.09 - 148.14 Perf YTD31.08%
Dividend2.44 P/FCF24.01 EPS past 5Y12.00% ROI10.50% 52W High-0.59% Beta0.53
Dividend %1.66% Quick Ratio4.00 Sales past 5Y4.50% Gross Margin80.50% 52W Low37.51% ATR3.82
Employees20000 Current Ratio4.40 Sales Q/Q10.70% Oper. Margin33.80% RSI (14)65.80 Volatility2.98% 2.70%
OptionableYes Debt/Eq1.37 EPS Q/Q21.80% Profit Margin25.70% Rel Volume1.44 Prev Close147.25
ShortableYes LT Debt/Eq1.26 EarningsOct 27 AMC Payout32.60% Avg Volume3.68M Price147.26
Recom2.40 SMA206.76% SMA506.87% SMA20019.46% Volume5,311,852 Change0.01%
08-Sep-14Reiterated RBC Capital Mkts Outperform $138 → $150
04-Aug-14Reiterated Argus Buy $135 → $140
30-Jul-14Reiterated RBC Capital Mkts Outperform $125 → $138
18-Jul-14Reiterated Deutsche Bank Buy $144 → $149
23-Apr-14Reiterated Oppenheimer Perform $121 → $122
21-Mar-14Reiterated Barclays Equal Weight $115 → $130
31-Jan-14Reiterated Argus Buy $130 → $135
20-Nov-13Reiterated Deutsche Bank Buy $138 → $142
29-Aug-13Reiterated UBS Buy $121 → $124
27-Aug-13Reiterated Barclays Overweight $105 → $115
31-Jul-13Reiterated Oppenheimer Perform $100 → $109
24-Apr-13Reiterated Deutsche Bank Buy $108 → $115
15-Apr-13Reiterated Barclays Equal Weight $90 → $105
08-Apr-13Reiterated RBC Capital Mkts Outperform $95 → $105
25-Jan-13Upgrade Argus Hold → Buy $96
24-Jan-13Reiterated UBS Buy $96 → $98
12-Sep-12Downgrade Robert W. Baird Outperform → Neutral $84
10-Sep-12Upgrade UBS Neutral → Buy $80 → $96
02-Aug-12Downgrade Argus Buy → Hold
15-Mar-12Resumed Stifel Nicolaus Hold
24-Oct-14 03:45PM  Will Amgen (AMGN) Disappoint in the Q3 Earnings Season? Zacks
23-Oct-14 05:39PM  Amgen To Webcast 2014 Business Review Meeting On October 28 PR Newswire
04:05PM  Amgen Announces Webcast of 2014 Third Quarter Financial Results PR Newswire
02:30PM  Novartis' Secukinumab Receives Favorable FDA Panel Vote Zacks
07:10AM  The Zacks Analyst Blog Highlights: AbbVie, Amgen, Regeneron, Pharmacyclics and Repros Therapeutics Zacks
22-Oct-14 07:00PM  17 trades in 91 seconds CNBC
05:59PM  Fast Money Final Trade: HD, HYG, MRK, AMGN CNBC
05:01PM  Biotechs Show Fed Chief's Not Much Of A Stock Analyst at Investor's Business Daily
01:40PM  Amgen Gains as Third Point Suggests Split Zacks
11:59AM  Four Reasons Why Amgen Won't Break Up at Barrons.com
11:46AM  Amgens Boss Makes a Prime Breakup Target for Loeb at New York Times
11:36AM  Third Point's Daniel Loeb Tells Amgen it's Time to Break up at TheStreet
11:25AM  Bernstein Analyst Was First on Amgen Split---But Missed Its 20% Rally at The Wall Street Journal
11:22AM  Amgen: splitting hairs at Financial Times
10:18AM  Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amgen Consider Breakup? Zacks
09:47AM  Add Amgen to the List of Activist Targets at Barrons.com
09:25AM  A.M. Roundup: New Managed ETFs from Global X, J.P. Morgan; Loeb Calls For Amgen Break Up at Barrons.com
09:23AM  [video] Dan Loebs Third Point Takes Aim at Amgen Break Up at Bloomberg
02:01AM  [$$] Amgen: $100 Billion Activist Target at The Wall Street Journal
21-Oct-14 07:56PM  Third Point urges Amgen to consider breakup at USA TODAY
07:36PM  Third Point urges Amgen to consider breakup AP
06:32PM  Hedge fund Third Point calls for splitting Amgen into two firms at Los Angeles Times
06:28PM  [$$] Third Point Wants Amgen to Explore Separation at The Wall Street Journal
05:54PM  Loeb urges Amgen to explore a break-up at Financial Times
05:42PM  The Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
04:29PM  Daniel Loeb urges Amgen to split into two companies at Fortune
04:22PM  The Plan to Drive Amgen Shares Up Over 70% at 24/7 Wall St.
04:22PM  Third Point's Loeb urges breakup of biotech company Amgen Reuters
04:03PM  Third Point, Loebs Hedge Fund, Urges Amgen to Consider a Breakup at New York Times
03:59PM  One Reason eBay (EBAY) Stock Is Up Today at TheStreet
03:42PM  Third Point wants Amgen to explore separation at MarketWatch
03:41PM  Amgen Statement Regarding Third Point Investment PR Newswire
03:19PM  Why Amgen (AMGN) Stock Is Rising in Afternoon Trading Today at TheStreet
03:02PM  Dan Loeb talks up Amgen stake; shares rise at CNBC
01:56PM  An Activist Hedge Fund Manager Thinks This $100 Billion Biotech Company Could Be Worth 80% More Business Insider
20-Oct-14 04:10PM  Amgen Sues Sanofi and Regeneron over PCSK9 Candidate Zacks
18-Oct-14 08:02AM  Celgene, Alexion Among 4 IBD 50 Medicals To Report at Investor's Business Daily
17-Oct-14 07:08PM  Amgen to join Gates Foundation in effort to produce Ebola drug at Los Angeles Times
04:25PM  AMGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
04:17PM  Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors PR Newswire
04:12PM  Trade-Ideas: Amgen (AMGN) Is Today's "Barbarian At The Gate" Stock at TheStreet
04:03PM  Amgen Announces 2014 Fourth Quarter Dividend PR Newswire
12:53PM  [$$] Amgen Files Patent Infringement Suit at The Wall Street Journal
12:16PM  Amgen Tests New Way to Make Ebola Drug to Boost Supply at Bloomberg
11:48AM  Two Tribes Go to War: Amgen Sues Regeneron for Patent Infringement at Barrons.com
09:55AM  [video] Positive for Regeneron: Cramer at CNBC
09:00AM  Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement PR Newswire
16-Oct-14 03:13PM  The Best-Selling Biologic Drugs at Forbes
13-Oct-14 08:40AM  UBS Very Positive on Top Biotech Stocks Ahead of Earnings at 24/7 Wall St.
10-Oct-14 06:35PM  Most Top Industry Groups Fall Harder Than Market at Investor's Business Daily
10:10AM  Short Interest in Biotech Becomes Company Specific at 24/7 Wall St.
09-Oct-14 04:05PM  Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia PR Newswire
03:44PM  Amgen Up on Positive Phase III Data on Psoriasis Biosimilar Zacks
08-Oct-14 04:04PM  Illumina Pads Gene Sequencing Lead With Pharma Deals at Investor's Business Daily
03:50PM  [video] Sears takes a hit at CNBC
03:40PM  Amgen says version of Humira meets study goal AP
12:01PM  Amgen's Humira copy succeeds in skin disease trial Reuters
10:20AM  Amgen's Data on Evolocumab Published in The Lancet Zacks
10:14AM  Amgen psoriasis drug succeeds late-stage trial Reuters
09:15AM  Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis PR Newswire
06-Oct-14 12:38PM  Will Biotech Beat This Earnings Season? at Barrons.com
01-Oct-14 07:01PM  The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol PR Newswire
05:00PM  Why October could be bad for biotech Talking Numbers
09:47AM  I'm Shocked, Shocked To Find That Pharma Is Paying Doctors! at Forbes
30-Sep-14 12:06PM  Amgen, Inc. Showing Strong Performance Despite Low Beta Benzinga
29-Sep-14 07:03PM  SEC lawsuit over Onyx insider trading can move forward -U.S. judge Reuters
04:00PM  Amgen Inc Conference Call on Kyprolis at ESMO scheduled for 4:00 pm ET today CCBN
01:03PM  AMGN, ACT And GILD, Pushing Drugs Industry Downward at TheStreet
26-Sep-14 04:20PM  Celldex (CLDX) Up on Pilot Study Initiation on CDX-301 Zacks
25-Sep-14 05:17PM  Biotech selloff: What to buy CNBC
05:17PM  [video] Biotech selloff: What to buy at CNBC
04:00PM  Inovio/GeneOne Life Science Collaborate for Ebola Vaccine Zacks
02:19PM  4 picks in biotech Yahoo Finance
08:31AM  Zacks Rank #1 Additions for Thursday Zacks
24-Sep-14 05:02PM  Amgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The European Society for Medical Oncology (ESMO) 2014 Congress PR Newswire
04:30PM  Celgene's Otezla Label Expanded to Include Plaque Psoriasis Zacks
01:27PM  Acorda To Buy Civitas, Gains Parkinson's Disease Drug at Investor's Business Daily
09:01AM  For Second Act, Acorda Drops $525 Million On Inhaled Parkinson's Drug at Forbes
02:30AM  ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise PR Newswire
23-Sep-14 03:45PM  Bayer/Regeneron Successfully Expand Eylea Label in Japan Zacks
22-Sep-14 09:00AM  Amgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab PR Newswire
19-Sep-14 05:26PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
18-Sep-14 05:24PM  Today's Market Thorns, Roses and All Time Highs... Yahoo Finance Blogs
04:35PM  Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies Zacks
17-Sep-14 06:15PM  Merck Posts Positive Data on Osteoporosis Drug Odanacatib Zacks
05:40PM  UCB-Amgen Reveals Positive Data on Romosozumab for PMO Zacks
05:12PM  The Market's Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
02:34PM  Amgen, Inc. Poised To Break Higher Benzinga
15-Sep-14 05:06PM  Biotech still place to be: Pro CNBC
05:06PM  [video] Biotech still place to be: Pro at CNBC
04:50PM  Biogen/AbbVie Report Positive Data on MS Drug Zinbryta Zacks
04:30PM  Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis PR Newswire
04:00PM  New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density PR Newswire
09:30AM  A Fabulous Pharma ETF ETF Trends
14-Sep-14 09:00PM  Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure PR Newswire
11-Sep-14 05:41PM  Medivation Eyes Blockbuster As Cancer Drug Gets An OK at Investor's Business Daily
03:30PM  Orexigen's Obesity Drug Contrave Approved by the FDA Zacks
09:20AM  Short Sellers Remain Vigilant Against Biotechs at 24/7 Wall St.
08:54AM  UPDATE: Morgan Stanley Reiterates On Amgen, Inc. Following Healthcare Conference Benzinga
07:59AM  The Zacks Analyst Blog Highlights: AbbVie, Infinity Pharmaceuticals, Keryx Biopharmaceuticals, Gilead and Amgen Zacks
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM
Harper Sean EEVP, Research & DevelopmentAug 05Sale127.2914,0001,782,12659,503Aug 07 04:22 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Option Exercise56.644,130233,91122,719May 22 05:15 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Sale112.834,130465,98418,589May 22 05:15 PM
Bradway Robert AChairman, CEO and PresidentMay 12Buy111.7789499,919185,013May 12 08:33 PM
Michael A KellyActing CFOApr 28Sale110.452,065228,07241,041Apr 29 05:48 PM
de Carbonnel FrancoisDirectorMar 06Option Exercise54.4410,000544,35025,364Mar 07 05:23 PM
de Carbonnel FrancoisDirectorMar 06Sale126.691,000126,69018,343Mar 07 05:23 PM
BALTIMORE DAVIDDirectorFeb 26Option Exercise62.555,000312,75031,879Feb 26 08:28 PM
HENDERSON REBECCA MDirectorFeb 13Option Exercise62.4120,0001,248,16025,549Feb 14 04:34 PM
HENDERSON REBECCA MDirectorFeb 13Sale123.5320,0002,470,6805,549Feb 14 04:34 PM
Bradway Robert AChairman, CEO and PresidentFeb 12Option Exercise62.5565,0004,065,750216,040Feb 14 04:19 PM
AMGEN INC10% OwnerDec 17Buy7.00272,1421,904,994541,399Dec 18 06:09 PM